Teva Pharmaceutical Industries Ltd. — Director's Dealing 2022

Mar 8, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)
CIK: 0000818686
Period of Report: 2022-03-04

Reporting Person: Dethlefs Sven (EVP, North America Commercial)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-03-04	Ordinary Shares	M	37939	—	Acquired	137396	Direct
2022-03-04	Ordinary Shares	M	13930	—	Acquired	151326	Direct
2022-03-04	Ordinary Shares	S	3904	$7.4825	Disposed	147422	Direct
2022-03-05	Ordinary Shares	M	24952	—	Acquired	172374	Direct
2022-03-07	Ordinary Shares	S	6993	$7.3667	Disposed	165381	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-03-04	Restricted Share Units	$	M	37939	Disposed		Ordinary Shares (37939)	Direct
2022-03-04	Restricted Share Units	$	M	13930	Disposed		Ordinary Shares (13930)	Direct
2022-03-04	Restricted Share Units	$	A	154155	Acquired		Ordinary Shares (154155)	Direct
2022-03-05	Restricted Share Units	$	M	24952	Disposed		Ordinary Shares (24952)	Direct

Footnotes

F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources
and Compensation Committee, the cash value of one ordinary share.

F3: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F4: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting
of the restricted share units listed in Table II.

F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.40 to $7.60, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.30 to $7.49, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

F7: Restricted share units were received on February 8, 2022 upon satisfaction of performance criteria and vested on March 4, 2022.

F8: Restricted share units were granted on March 4, 2019, with 13,930 having vested on each of March 4, 2021 and March 4, 2022, and 13,931 vesting on March 4, 2023.

F9: Restricted share units were granted on March 4, 2022, with 38,538 vesting on each of March 4, 2023, March 4, 2024 and March 4, 2025, and 38,541
vesting on March 4, 2026.

F10: Restricted share units were granted on March 5, 2021, with 24,952 having vested on March 5, 2022, 24,952 vesting on each of March 5, 2023 and March 5, 2024, and 24,953 vesting on March 5, 2025.